Trial Profile
Long Term Follow-up of Subjects Exposed to Genetically Engineered Tumor Antigen Specific T Cell Receptors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Afamitresgene autoleucel (Primary) ; MAGE A-10 TCR-transduced lymphocytes (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Adverse reactions
- Sponsors Adaptimmune
- 05 Jan 2021 Status changed from recruiting to discontinued.
- 01 Aug 2019 According to an Adaptimmune Media release, enrollment in this trial is expected to be closed by end of 2019.
- 23 May 2018 Status changed from not yet recruiting to recruiting.